A Phase 2A Trial of DT402 for Autism Spectrum Disorder
NCT07303907
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
20
Enrollment
INDUSTRY
Sponsor class
Conditions
Autism Spectrum Disorder
ASD
Interventions
DRUG:
DT402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA))
Sponsor
Definium Therapeutics US, Inc.